概括
一项案例研究强调,林纳利普坦是一种2型糖尿病药物,可能会引起妄想. 停止服用利纳格利普坦并转换为恩帕格利弗洛辛导致患者完全康复,这表明药物和妄想之间存在联系.
科学领域:
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 2型糖尿病的管理通常涉及具有潜在副作用的药物.
- 妄想症是老年人常见的疾病,其特征是急性混乱.
- 肠-大脑轴在神经功能和炎症中起着至关重要的作用.
研究的目的:
- 报告林加利普坦的潜在不良影响,特别是妄想.
- 调查林加利普坦使用与2型糖尿病患者妄发作的关联.
- 强调在的差异诊断中考虑药物副作用的重要性.
主要方法:
- 一份病例报告显示,一名77岁的男性患有2型糖尿病,出现急性混乱.
- 进行了临床检查,实验室测试和神经成像 (CT脑,MRI脑,胸部X射线).
- 使用4AT (4A测试) 评分来评估妄想症的严重程度.
主要成果:
- 患者在从甲胺转换为林加利普坦后48小时出现了急性混乱.
- 所有标准的医疗检查,包括血液检查和成像检查,对于造成混的原因来说都不显著.
- 停用林加利普坦和启动Empagliflozin导致狂妄症症状完全消失.
结论:
- 利纳格利普坦可能与妄想有关,可能是通过影响肠道微生物组和肠-大脑轴的机制.
- 这是第一个报告的临纳利普坦诱导的妄想病例.
- 需要进行进一步的研究,以探索二乙酶-4抑制剂,肠道运动性和神经功能之间的联系.
相关概念视频
Patient-centered Care
3.0K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.0K
Drug Dosing: Obese Patients
242
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
242
Drug Dosing: Geriatric Patients
229
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
Pharmacokinetics in Pediatric Patients: Drug Distribution
285
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
285
Pharmacokinetics in Pediatric Patients: Drug Metabolism
212
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
212
Pharmacodynamics in Geriatric Patients: Effects of Age
202
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
202


